Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib

Lung Cancer

Volumn 66, Issue 1, 2009, Pages 114-119

  Ma, Fei ^a   Sun, Tong ^a   Shi, Yuankai ^a   Yu, Dianke ^a   Tan, Wen ^a   Yang, Ming ^a   Wu, Chen ^a   Chu, Datong ^a   Sun, Yan ^a   Xu, Binghe ^a   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Clinical outcome; EGFR; Gefitinib therapy; Lung cancer; Polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIMPLE SEQUENCE REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 68949208058     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.12.025     Document Type: Article

References (40)

1. Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs 12 (2008) 587-596
2. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 3016-3024
5. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
6. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
7. Lee D.H., Han J.Y., Lee H.G., et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11 (2005) 3032-3037
8. van Puijenbroek R., Bosquee L., Meert A.P., et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J 29 (2007) 128-133
9. Ando M., Okamoto I., Yamamoto N., et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with Gefitinib. J Clin Oncol 24 (2006) 2549-2556
10. Bonjour J.P., Chevalley T., Rizzoli R., et al. Gene-environment interactions in the skeletal response to nutrition and exercise during growth. Med Sport Sci 51 (2007) 64-80
11. Saposnik B., Reny J.L., Gaussem P., et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 103 (2004) 1311-1318
12. Walgren R.A., Meucci M.A., and McLeod H.L. Pharmacogenomic discovery approaches: will the real genes please stand up?. J Clin Oncol 23 (2005) 7342-7349
13. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med 350 (2004) 2129-2139
14. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science 304 (2004) 1497-1500
15. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with Gefitinib. J Clin Oncol 23 (2005) 2493-2501
16. Bell D.W., Lynch T.J., Haserlat S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT Gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
17. Sharma S.V., Bell D.W., Settleman J., et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007) 169-181
18. Amador M.L., Oppenheimer D., Perea S., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64 (2004) 9139-9143
19. Perea S., Oppenheimer D., and Amador M. Genotypic bases of EGFR inhibitors pharmacological actions. Proc Am Soc Clin Oncol 23 196 (2004) A3005
20. Brandt B., Meyer-Staeckling S., Schmidt H., et al. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 12 (2006) 7252-7260
21. Chrysogelos S.A. Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res 21 (1993) 5736-5741
22. Etienne-Grimaldi M.C., Pereira S., Magne N., et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 16 (2005) 934-941
23. Han S.W., Kim T.Y., Lee K.W., et al. EGFR mutation and intron 1 CA repeat polymorphism as predictive markers of Gefitinib responsiveness in non-small cell lung cancer (NSCLC). J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 18S (2006) A7173
24. Liu W., Innocenti F., Wu M.H., et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65 (2005) 46-53
25. Rudin C.M., Liu W., Desai A., et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26 (2008) 1119-1127
26. Liu G., Gurubhagavatula S., Zhou W., et al. Epidermal growth factor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 8 (2008) 129-138
27. Gregorc V., Hidalgo M., Spreafico A., et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 83 (2008) 477-484
28. Nomura M., Shigematsu H., Li L., et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4 (2007) e125
29. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
30. Stram D.O. Software for tag single nucleotide polymorphism selection. Hum Genomics 2 (2005) 144-151
31. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., et al. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67 (2007) 9609-9612
32. Kimchi-Sarfaty C., Oh J.M., Kim I.-W., et al. A "Silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
33. Nackley A.G., Shabalina S.A., Tchivileva I.E., et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314 (2006) 1930-1933
34. Capon F., Allen M.H., Ameen M., et al. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 13 (2004) 2361-2368
35. Nielsen K.B., Sorensen S., Cartegni L., et al. Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 80 (2007) 416-432
36. Moriai T., Kobrin M.S., Hope C., et al. A variant epidermal growth factor receptor exhibits altered type transforming growth factor binding and transmembrane signalling. Proc Natl Acad Sci USA 91 (1994) 10217-10221
37. Liu W., Wu X., Zhang W., et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13 (2007) 6788-6795
38. n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol 570 (2007) 175-181
39. Liu W., Montenegro R.C., Zhang W., et al. Response to EGFR inhibitors in fibroblast cell lines and its association with germline polymorphisms. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 18S (2006) A13167
40. Dubey S., Stephenson P., Levy D.E., et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 1 (2006) 406-412